These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 20304368

  • 1. [Protocol for inducing infliximab tolerance in a patient with psoriatic spondylarthritis].
    Gallardo R, Fobelo MJ, Pastor C, Orta-Cuevas JC.
    Farm Hosp; 2010; 34(2):94-6. PubMed ID: 20304368
    [No Abstract] [Full Text] [Related]

  • 2. Pulmonary sarcoidosis in a patient with psoriatic arthritis during infliximab therapy.
    Izzi S, Francesconi F, Visca P, Altieri A, De Mutiis C, Trevisan G, Bonifati C.
    Dermatol Online J; 2010 May 15; 16(5):16. PubMed ID: 20492833
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Adverse reactions to infliximab and the outcome of desensitization.
    Mourad AA, Boktor MN, Yilmaz-Demirdag Y, Bahna SL.
    Ann Allergy Asthma Immunol; 2015 Aug 15; 115(2):143-6. PubMed ID: 26093777
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al.
    Cisternas M, Gutiérrez M, Jacobelli S.
    Arthritis Rheum; 2002 Nov 15; 46(11):3107-8; author reply 3108-9. PubMed ID: 12428265
    [No Abstract] [Full Text] [Related]

  • 9. [Effectiveness of infliximab in patients with inflammatory arthritis refractory to conventional treatment].
    Labarca C, Massardo L, García PI, Jacobelli S.
    Rev Med Chil; 2003 Oct 15; 131(10):1157-64. PubMed ID: 14692306
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Infectious risk].
    Calabuig E, Salavert M.
    Actas Dermosifiliogr; 2008 Jul 15; 99 Suppl 4():14-22. PubMed ID: 19080987
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment.
    Nikas SN, Voulgari PV, Takalou IP, Katsimbri P, Drosos AA.
    Ann Rheum Dis; 2005 Nov 15; 64(11):1665-7. PubMed ID: 16227426
    [No Abstract] [Full Text] [Related]

  • 18. Biologics and infections: lessons from tumor necrosis factor blocking agents.
    Wallis RS.
    Infect Dis Clin North Am; 2011 Dec 15; 25(4):895-910. PubMed ID: 22054762
    [Abstract] [Full Text] [Related]

  • 19. Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience.
    Voulgari PV, Venetsanopoulou AI, Epagelis EK, Alamanos Y, Takalou I, Drosos AA.
    Ann Rheum Dis; 2007 Feb 15; 66(2):270-1. PubMed ID: 17068063
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.